First patients enrolled in HIT-CF!
25 people from 5 countries have been included so far: 13 people from the Netherlands, 8 from the Czech Republic, 2 from Israel, 1 from Austria and 1 person from Germany (both via the Netherlands). Also in Belgium, the team is now ready to start enrolling patients. This brings the total number of countries where people can participate in HIT-CF to 6 (green in map). We expect 23 extra hospitals in Portugal, Spain, France, United Kingdom, Italy, Sweden, Poland, Denmark and Switzerland (orange in map) to start including people in the following months!

HIT-CF welcomes Proteostasis Therapeutics and Eloxx Pharmaceuticals to the consortium!
Because their drug candidates aim to improve CFTR function in new ways, people with specific CFTR mutations that previously could not participate in the study are now able to join. Please check the updated criteria here. To learn more about the pharmaceutical companies and their new compounds, read the press releases here.

Our labs started drug candidate testing in the first organoids!
Over the past year, our lab technicians in Utrecht, Leuven and Lisbon have been working hard to obtain standardized organoid screening results. They have now successfully completed this test phase.

The organoids grown from the intestinal tissue from the first included patients have been shipped to our three labs. There, our lab technicians have started with testing the drug candidates in the organoids (screening).

Do you want to participate, or do you want more info about the HIT-CF project? Visit the HIT-CF website or send an e-mail to HITCF@umcutrecht.nl